Acromegaly Update

Ethan Weiss
  • 5.0 (1)
  • Life Sciences
  • Updated Weekly

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.

  1. 6d ago

    Acromegaly Update — Monday July 20, 2026

    A quiet week for acromegaly research was anchored by a strong AI-diagnosis paper in JCEM, while rare disease headlines swung between a startup's ultrasound gene-therapy bombshell and a somber earnings-style readout on a rare endocrine disorder.

  2. Jul 13

    Acromegaly Update — Monday July 13, 2026

    It was a quiet week for new acromegaly research, but the rare disease industry delivered its biggest story of the year — Vertex's $10 billion acquisition of Crinetics Pharmaceuticals, maker of the acromegaly drug Palsonify, directly linking this week's two segments.

  3. Jul 6

    Acromegaly Update — Monday July 6, 2026

    It's a thin week for acromegaly-specific research — just one mechanistic study on tumor biology — but rare disease dealmaking was busy, headlined by Ipsen's ~$800M bet on a kidney-transplant antiviral and an FDA age expansion for Vertex's CRISPR therapy Casgevy.

  4. Jun 29

    Acromegaly Update — Monday June 29, 2026

    Paltusotine's four-year open-label data confirm durable oral control of acromegaly in patients switched from injections, while the rare disease industry absorbs a landmark Sangamo bankruptcy, a well-funded gene-editing entrant in AATD, and a new build-to-buy cardiomyopathy venture from Merck KGaA.

  5. Jun 22

    Acromegaly Update — Monday June 22, 2026

    A rich week in acromegaly research — new data on renal complications, a precision medicine framework, a high-risk co-secreting tumor phenotype, and cancer risk analyses — while the rare disease industry continues to see a wave of FDA regulatory reversals benefiting gene therapy developers.

  6. Jun 15

    Acromegaly Update — Monday June 15, 2026

    Surgical technique innovation and a JCEM editorial from two giants of the field reshape how we think about curing GH-secreting tumors and managing cancer risk in acromegaly, while the rare disease sector sees a burst of late-stage deal-making and platform financing that signals strong investor conviction in gene-silencing technologies.

  7. Jun 8

    Acromegaly Update — Monday June 8, 2026

    A landmark JCEM special issue lands this week with five major reviews and original studies that collectively reset the clinical playbook for acromegaly — from emerging oral therapies to the underappreciated mortality burden — while in the rare disease industry, Alnylam bets $2 billion on AI-designed RNA medicines, a controversial FDA voucher program faces calls for reform, and a new market forecast projects orphan drug sales above $400 billion by 2032.

  8. Jun 1

    Acromegaly Update — Monday June 1, 2026

    New Pituitary research this week highlights the cardiac and bone risks that persist even in treated acromegaly patients, while the rare disease industry grapples with a mixed regulatory environment — one notable ASCO data release and continued fallout from FDA leadership turnover.

See All (14)

Ratings & Reviews

About

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.

Information

  • Creator
    Ethan Weiss
  • Years Active
    2026
  • Episodes
    14
  • Rating
    Clean
  • Copyright
    © Ethan Weiss / Marea Therapeutics
  • Show Website
    Acromegaly Update